{"bill":{"bill_id":1343223,"change_hash":"4343f5d313fc0cfc28abcff37986af4a","session_id":1658,"session":{"session_id":1658,"state_id":52,"year_start":2019,"year_end":2020,"prefile":0,"sine_die":1,"prior":1,"special":0,"session_tag":"Regular Session","session_title":"2019-2020 Regular Session","session_name":"116th Congress"},"url":"https:\/\/legiscan.com\/US\/bill\/HB5927\/2019","state_link":"https:\/\/www.congress.gov\/bill\/116th-congress\/house-bill\/5927\/all-info","completed":0,"status":1,"status_date":"2020-02-18","progress":[{"date":"2020-02-18","event":1},{"date":"2020-02-18","event":9}],"state":"US","state_id":52,"bill_number":"HB5927","bill_type":"B","bill_type_id":"1","body":"H","body_id":114,"current_body":"H","current_body_id":114,"title":"Safe Medicine Act","description":"To direct the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination.","pending_committee_id":2302,"committee":{"committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"},"referrals":[{"date":"2020-02-18","committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"}],"history":[{"date":"2020-02-18","action":"Introduced in House","chamber":"H","chamber_id":114,"importance":0},{"date":"2020-02-18","action":"Referred to the House Committee on Energy and Commerce.","chamber":"H","chamber_id":114,"importance":1}],"sponsors":[{"people_id":9197,"person_hash":"cw1v2ewn","party_id":"2","state_id":52,"party":"R","role_id":1,"role":"Rep","name":"Bill Posey","first_name":"Bill","middle_name":"","last_name":"Posey","suffix":"","nickname":"","district":"HD-FL-8","ftm_eid":12998616,"votesmart_id":24280,"opensecrets_id":"N00029662","knowwho_pid":193543,"ballotpedia":"Bill_Posey","sponsor_type_id":1,"sponsor_order":1,"committee_sponsor":0,"committee_id":0,"state_federal":0}],"sasts":[{"type_id":8,"type":"Related","sast_bill_number":"HB5982","sast_bill_id":1351663}],"subjects":[{"subject_id":13304,"subject_name":"Health"},{"subject_id":13126,"subject_name":"Administrative law and regulatory procedures"},{"subject_id":13405,"subject_name":"Asia"},{"subject_id":13732,"subject_name":"China"},{"subject_id":13146,"subject_name":"Congressional oversight"},{"subject_id":13593,"subject_name":"Drug safety, medical device, and laboratory regulation"},{"subject_id":22688,"subject_name":"Government studies and investigations"},{"subject_id":13206,"subject_name":"Health care costs and insurance"},{"subject_id":13210,"subject_name":"Health information and medical records"},{"subject_id":13214,"subject_name":"Health technology, devices, supplies"},{"subject_id":13701,"subject_name":"Manufacturing"},{"subject_id":13490,"subject_name":"Prescription drugs"},{"subject_id":13260,"subject_name":"Public contracts and procurement"},{"subject_id":13416,"subject_name":"Trade restrictions"}],"texts":[{"doc_id":2147605,"date":"2020-02-22","type":"Introduced","type_id":1,"mime":"application\/pdf","mime_id":2,"url":"https:\/\/legiscan.com\/US\/text\/HB5927\/id\/2147605","state_link":"https:\/\/www.congress.gov\/116\/bills\/hr5927\/BILLS-116hr5927ih.pdf","text_size":324811,"text_hash":"6f3dc426cd3316e614455f5ee671c074"}],"votes":[],"amendments":[],"supplements":[],"calendar":[]}}